The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration.
One gram each of FCE 22101 and its acetoxymethyl ester (FCE 22891) were administered sequentially to six healthy volunteers. After intravenous administration Cmax was 167 mg/l, and the elimination half-life 0.8 h. Following oral administration Cmax was 6.9 mg/l and the elimination half-life 0.6 h. Penetration into inflammatory fluid was rapid, and the percentage penetration 86.1 and 60.9% following oral and intravenous dosing respectively. Urine recovery was greater after intravenous administration (31%) than after oral (11%).
Webberley
J M
JM
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
Wise
R
R
Andrews
J M
JM
Ashby
J P
JP
Wallbridge
D
D
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001768:Blister / Q000378:metabolism; D015780:Carbapenems; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007769:Lactams; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D007769:Lactams; C041561:FCE 22891; C040033:ritipenem